Bernstein’s 34th Annual

Strategic Decisions Conference

Mike Mahoney

Chairman and Chief Executive Officer

2

Safe Harbor for Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could differ materially from the expectations and projections expressed or implied by our forward-looking statements.

Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings “Risk Factors” and “Safe Harbor for Forward-Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Non-GAAP Measures:This document contains non-GAAP measures (denoted with *) in talking about our company’s performance. The reconciliations of those non-GAAP measures to their most comparable GAAP measures are contained within this document including appendices attached to theend of this presentation.

Financial Disclaimers:

Operational growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations. Organic growth rates are non-GAAP measures that exclude the impact of changes in foreign currency exchange rates and the sales from significant acquisitions (Symetis SA, the American Medical Systems male urology portfolio and EndoChoice Holdings, Inc.) in the relevant periods.

We define Emerging Markets as including certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Currently, we have 20 countries in our definition of Emerging Markets.

Market Estimates:

Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates.

3

Regulatory Disclaimers

Product Regulatory Disclaimer

Implantable Cardiac Monitor Device under development. Not available for use or sale worldwide.

EMPOWER™ Leadless Pacer Device under development. Not available for use or sale worldwide.

Apama RF Balloon Catheter Device under development. Not available for use or sale worldwide.

DrectSense™ Technology Device under development. Not available for use or sale worldwide.

Ranger™ Drug-Coated BalloonCE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.

Drug Eluting Stent – Below-the-knee indication Device under development. Not available for use or sale worldwide.

Eluvia™ Drug eluting self-expanding SFA stentCE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.

Lotus Edge™ U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.

ACURATE™ Self Expanding Valve PlatformCE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.

WATCHMAN™ FLX Pending CE Mark. Not available for use or sale in the U.S.

4

Our Mission and Values

CaringMeaningful

Innovation

High

Performance

Global

CollaborationDiversity Winning Spirit

Boston Scientific is dedicated to

transforming lives through innovative

medical solutions that improve the

health of patients around the world.

5

What to expect from BSX

1. Living BSX values

• Transforming patients’ lives through meaningful innovation and a “WINNING SPIRIT”

2. Driving category leadership and expanding globally

• Gaining share globally: Portfolio innovation & compelling economic value drivers

• Emerging markets: Building scale & new capabilities to increase patient access

3. Enhancing long term outlook: entering into multiple large & high growth markets

• Diversifying into large high-growth markets with differentiated portfolio & capabilities

• Multiple launches into $16B of new market opportunities

4. Consistently delivering revenue and EPS growth in top tier of peer group

• 2015-2017: 3 year avg. organic revenue* growth +7% and EPS CAGR +14.5%

• 2018E-2020E: 3 year organic revenue* CAGR +5-8% and EPS CAGR +DD

5. Building shareholder value with disciplined capital allocation strategy: more to come

• Strong free cash flow* generation: estimated $6.3B+ cumulative in years 2018-2020

• Rigorous and balanced approach to M&A

6$0.3B, +14%

Boston Scientific At-A-Glance

2017 Revenue and Operational Growth*: (Total company: $9.0B, 8%; Organic Growth* 7%)

Rhythm Management

Interventional Cardiology

Structural Heart

Peripheral Interventions

$2.4B, +6%

$1.1B, +7%

$275M+

CRM Electrophysiology

$1.9B, +2%

Endoscopy

Urology & Pelvic Health

Neuromodulation

$1.6B, +12%

$0.6B, +14%

$1.1B, +12%

7

Reported Revenue, Y/Y Operational* growth

Y/Y Organic* growth rates

18.9%

20.2%

22.3%

24.1%

2013 2014 2015 2016 2017

$7.1

$7.4$7.5

$8.4

$9.0

2013 2014 2015 2016 2017

+2%

+6%+8%

+12%

+8%

+4%+5%

+10%

+7%

$0.73

$0.84

$0.93

$1.11

2013 2014 2015 2016 2017

+11%

+15%

+11%

+20%

+13%

$1.26

High Performance Culture and Track Record

Adjusted EPS*RevenueAdjusted Operating

Margin*

Sales growth consistently > mktw/ avg. 7% organic* growth

’15-’17E

Delivering on marginexpansion goals

Consistent double digit adj. EPS* growth: 14.5% CAGR

’15-’17

25.0%

8

Estimated Market Growth Rates

Diversified and Durable Growth Profile

Low

Growth

35%

Moderate

Growth

50%

Low

Growth

46%

Moderate

Growth

47%

2017 Revenue Mix

$9.0B

2020E Revenue Mix2012 Revenue Mix

$7.2B

High Growth Mkt (10%+ CAGR): SCS, TAVR, LAAC, EP, DBS, PI Drug Eluting, ICM

High

Growth

7%High

Growth

15%

Low

Growth

25%

Moderate

Growth

50%

High

Growth

25%

Low Growth Mkt (0 - 3% CAGR): Pacers, Defibrillators, DES

Moderate Growth Mkt (4 - 9% CAGR): Endo, UroPH, PI (ex DES & DCB), Int. Oncology, IC (ex. SH, DES)

9

Strong Product Pipeline Supports

Long Range Plan Growth Targets

2020E / 2021E

Coronary Therapies

• SynergyTM DES line extensions

Structural Heart

• WATCHMAN FLXTM LAAC Device – U.S.

• ACURATE neo2TM Valve System –U.S./Japan

• ACURATETM Valve System – size matrix expansion

• LOTUS EdgeTM Valve** size matrix expansion

Peripheral Interventions

• RangerTM SFA DCB – U.S.

• SAVALTM Drug Eluting Stent BTK

CRM/EP

• Leadless Pacing/modular CRM – EU

• Force Sensing Catheter – U.S.

Neuromodulation

• SCS & DBS next gen – U.S./EU

Endo

• EUS portfolio & indication expansion –U.S./EU

• Pulmonary diagnostics

• AxiosTM stent expanded Indications – U.S.

Urology/Pelvic Health

• Multiple launches in Stone

• Multiple launches in Men’s Health

• Next gen Greenlight fiber for BPH

2018E 2019E

Coronary Therapies• SynergyTM DES line extensions• Multiple launches in Complex PCI

Structural Heart• WATCHMAN FLXTM LAAC Device – EU• WATCHMANTM LAAC Device – Japan• ACURATETM Valve System – Int’l

expansion• LOTUS EdgeTM Valve System** – U.S. &

EU

Peripheral Interventions• EluviaTM SFA DES - U.S.• Interventional Oncology Embolic Coils

CRM/EP• ICM Monitoring & Dx• Force Sensing Catheter – EU• Apama RF PVI Balloon – EU

Neuromodulation• Expanded DBS platform

Endo• SpyGlassTM Visualization System - next

gen • New launches in Infection Prevention• New launches in Biliary

Urology/Pelvic Health• LithoVueTM Ureteroscope next gen • 5 additional launches in Stone

Coronary Therapies

• 5 launches in Complex PCI

Structural Heart

• ACURATETM Aortic Valve System – OUS Expansion

• ACURATE neo2TM Aortic Valve System– EU

PI

• 3 launches in Arterial and Venous portfolio

CRM/EP

• ResonateTM CRT-D w/ HeartLogicTM HF Alert

• Rhythmia HDxTM Mapping System w/ LUMIPOINTTM

• DirectSenseTM Rx Catheter – EU/U.S.

Neuromodulation

• Spectra WaveWriterTM SCS System

• VerciseTM DBS system – U.S.

Endoscopy

• New launches in Infection Prevention (valves, kits)

• SpyGlassTM DS II Visualization System & cholangioscopy tools

• OriseTM Endoluminal Surgery portfolio

• AxiosTM Transluminal Stent – OUS expansion

Urology/Pelvic Health

• 4 launches in Stone

**Intend to launch Lotus in the U.S. & EU in 2019 pending final testing & regulatory approvals

All launches are WW, unless otherwise noted

10

Compelling opportunity beyond 2020 for 30%+ adjusted OM*

2013 2014 2015 2016 2017 2020E

25.0%24.1%

30+%

22.3%

20.2%

18.9%

~+300 bps

SG&A

productivity

Accretive new

products

Launches &

commercial

scale of key

products

R&D efficiencies

5-10% annual

standard cost

improvements

Track Record of Driving Operating Margin Expansion

AND Significant Future Opportunity

28%

Longer Term

Goal

11

Strong Cash Flow Generation Outlook

AND Limited Reserved Contingencies 2018-2020E

Strong Free Cash Flow*: 2016-2020E

Improved Ability to DeployCumulative Free Cash Flow*

** Based on adjusted free cash flow. Refer to non-GAAP reconciliations

80%90%

2015-2017: ~$4.7B

2018E-2020E: ~$6.3B

10%

Reserved Contingencies**

M&A or Returning Cash to Shareholders

20%10%

2016 2017 2018E 2019E 2020E

$1.6B

$1.7B

~$1.9B

~$2.1B

~$2.3B

12

VenturePortfolio

Tuck-in M&A

Pipeline

Disciplined & Balanced Approach to M&A

2011 - 2012 - 2013 - 2014 - 2015 - 2016 - 2017 - 2018

Peripheral

Vasc.

LumenR

Portfolio of 30+ Companies

in Selected Spaces:

• Mitral repair / replace

• HF Diagnostic / Therapeutic• Venous• Electrophysiology

• Overactive bladder

• Micro stimulation• Benign Prostatic Hyperplasia (BPH)• Autonomic Modulation Therapy (AMT)

Securus Medical

Group

13

✓ Tax court dispute concluded for tax years 2001 – 2010

✓ Exploring ways to reinvest this one-time non-GAAP benefit into our LT tax structure• Goal is to reduce our annual adjusted ETR in 2019+ below the 15% rate previously disclosed

✓ Expect to resolve tax years 2011 – 2013 before YE 2018 on the same basis

Finalization of IRS Stipulation of Settled Issues

Net payments expected to be approx. $600M

• Includes interest

• Payments are expected to be made within 3

months

One-time, non-cash adj. tax benefit of $70-80M to

be recorded in Q2

No impact to our 2018 estimated

annual adjusted ETR

• Will look to reinvest this

benefit in Q3 and Q4

• On a GAAP basis, the one-time, non-cash benefit is

$225-250M

• Non-GAAP benefit is

based on how reserves were originally booked

• Given timing, may

see variability in quarterly tax rates

• No change to our

2018 full-year adjusted EPS

guidance

14

Recent Awards and Recognitions Reflect

Winning Spirit Culture that Drives Results

Recognized for progressive life/work

policies and programs

Ranked #35 based on employee ratings

Ranked #16 in the U.S.Ranked #3 on U.S. Large Company list

Scored 100% for the 4th consecutive year

Scored 100% for the 2nd year in a row

Highest recognition for Guard/Reserve

employee support

Ranked 6th inindustry category

15

Appendix A

Non-GAAP Reconciliations

16

Use of Non-GAAP Measures

17

Appendix A: Non-GAAP Reconciliations

18

Appendix A: Non-GAAP Reconciliations

Adjusted Free Cash Flow (in millions)Cumulative 2015-2017ꝉ 2017 2016ꝉ 2015ꝉ

Operating Cash Flow, as reported $ 3,299 $ 1,426 $ 1,182 $ 691

Plus: Proceeds on disposals of property, plant and equipment 29 - 29 -

Less: Purchases of property, plant and equipment 942 319 376 247

Free Cash Flow 2,386 1,107 835 444

Plus: Restructuring Payments 248 72 81 95

Plus: Earnouts 128 14 57 57

Plus: Special Tax Refunds/Credits (387) (239) (74) (74)

Plus: Legal Settlements 2,148 694 701 753

Plus: Other 194 81 22 91

Adjusted Free Cash Flow $ 4,717 $ 1,729 $ 1,622 $ 1,366

ꝉ - Certain prior year balances within our Consolidated Statement of Cash Flow have been updated to reflect the adoption of ASC Update 2016-15 and ASC Update 2016-18. Please refer to our annual report on Form 10-K for the period ended December 31, 2017 for additional details.

Adjusted Free Cash Flow (in billions)Cumulative

2018E-2020Eꝉ 2020Eꝉ 2019Eꝉ 2018Eꝉ

Operating Cash Flow, estimated GAAP $ - $ - $ - $ -

Plus: Proceeds on disposals of property, plant and equipment - - - -

Less: Purchases of property, plant and equipment - - - -

Free Cash Flow - - - -

Plus: Special Adjustments - - - -

Adjusted Free Cash Flow $ 6.3 $ 2.3 $ 2.1 $ 1.9

ꝉ - Components of the reconciliation of operating cash flow, as reported, are not currently available.

19

Appendix A: Non-GAAP Reconciliations

FY2017 Net Sales Growth as compared to FY2016

As Reported

Less: Impact of Foreign

Currency Operational*

Less: Impact of Significant

Acquisitions Organic*

Interventional Cardiology 6.2% 0.1% 6.1%

Peripheral Interventions 6.5% -0.1% 6.6%

Cardiovascular 6.3% 0.0% 6.3%

Cardiac Rhythm Management 2.5% 0.2% 2.3%

Electrophysiology 14.5% 0.1% 14.4%

Rhythm Management 3.9% 0.2% 3.7%

Endoscopy 12.4% 0.1% 12.3%

Urology & Pelvic Health 11.8% 0.2% 11.6%

Neuromodulation 14.2% 0.1% 14.1%

MedSurg 12.5% 0.1% 12.4%

Total Company 7.9% 0.1% 7.8% 1.2% 6.6%

20

The following is an explanation of the adjustments that management excluded from GAAP measures to calculate the following forward-looking non-GAAP financial measures:

Adjusted Gross Margin: Excludes from GAAP gross margin the impacts of forecasted acquisition-and divestiture- and restructuring-related charges or credits.

Adjusted SG&A: Excludes from GAAP SG&A the impacts of forecasted acquisition- and divestiture-and restructuring-related charges or credits.

Adjusted R&D: Excludes from GAAP R&D the impacts of forecasted acquisition- and divestiture-and restructuring-related charges or credits.

Adjusted Operating Margin: Excludes from GAAP operating margin the impacts of forecasted acquisition- and divestiture- and restructuring- and restructuring-related charges or credits, and amortization expense.

Adjusted Tax Rate: Excludes from GAAP tax rate the tax impacts related to forecasted acquisition-and divestiture- and restructuring- and restructuring-related charges or credits, and amortization expense.

Adjusted Free Cash Flow: Adjusts GAAP operating cash flow to include the impacts of forecasted capital expenditures and excludes the impact of estimated after-tax acquisition- and divestiture-, restructuring- and litigation-payments.

Please refer to our Safe Harbor for forward-looking statements disclosure in conjunction with any forward looking information presented within.

Appendix A: Forward-Looking Non-GAAP

Financial Measures